MedTech booster Ajax Health reels in $120M in series B round

rocket launch
Ajax provides C-suite management and capital to lift companies out of the early clinical stages, with the goal of an eventual merger, sale or IPO. Currently, it focuses on cardiology subspecialties. (Pixabay)

Ajax Health, which helps build out and support other emerging medical device and healthcare technology companies, raised $120 million in a financing round to support its entrepreneurial endeavors.

The Menlo Park, California-based platform company’s new stakeholders include ICONIQ Capital, HealthQuest Capital, Polaris Partners, WTI and others. Ajax’s founding investors, KKR and Aisling Capital, also participated in the oversubscribed series B round.

“Their confidence in Ajax underscores the opportunity that Ajax sees to accelerate investment and innovation in an undervalued medical technology sector,” founder Duke Rohlen said in a statement.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

Rohlen is known for leading peripheral artery disease firm FoxHollow Technologies and drug-coated balloon developer CV Ingenuity, selling both companies for a combined windfall of over $1 billion. Rohlen also served as CEO of nasal implant manufacturer Spirox, which is now part of Stryker.

“There is a significant need in the medical device space for capital to be deployed into differentiated technologies that leverage seasoned operational teams and rational business models,” Rohlen said.

RELATED: PE firm KKR leads $45M to back minimally invasive nasal valve collapse implant

Ajax—formed in 2017 with a $95 million investment from KKR, Aisling Capital and Rohlen—provides C-suite management services, human resources and financial capital for its portfolio of companies, but does not host them in its own facilities, compared to an incubator. The endgame of Ajax’s tenure with a company typically culminates with a merger, sale or IPO listing, after working to derisk the product.

Currently, the company focuses on technologies related to the electrophysiology of heart rhythms, including diagnostics and therapeutics, as well as structural heart interventions and other cardiac subspecialties. Ajax is also eyeing opportunities in the ENT space, according to a company spokesperson.

Last year, Ajax invested in Advanced Cardiac Therapeutics, which raised $45 million to develop its ablation catheter for treating atrial fibrillation and other arrhythmias. Those funds were slated to support clinical studies as well as regulatory submissions in Europe and the U.S.

Suggested Articles

Qiagen’s investors turned down Thermo Fisher’s multibillion-dollar takeover proposal, following rocketing demand for its testing products.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.